Elsevier Patient Research Beta Contact Us | Terms & Conditions | Privacy Policy | About

Elsevier is the world's leading publisher of Medical Information. We are proud to make available our Patient Research option as a Beta program for patients, or friends/family of patients, who have a medical need for information regarding a medical situation for them or someone they know. This Beta program provides the article you request for free, with a small handling fee, $4.95. After ordering the article and confirmation of payment, we will e-mail the document to you typically within 2 hours, but no longer than 24 hours.

Androgen Receptor Blockade in Experimental Combination Therapy of Pancreatic Cancer
Journal of Surgical Research, Volume 142, Issue 2, October 2007, Pages 378-386

Abstract: BackgroundReports on hormone receptor expression of pancreatic cancer (PaCa) cells and treatment responses to antihormonal therapy are still conflicting.MethodsEight human PaCa cell lines were tested for androgen receptor (AR) protein levels by Western blot analysis. Cell proliferation in vitro was measured by sulforhodamine B analysis. AR agonists and inhibitors included dihydrotestosterone (DHT), testosterone (T), and flutamide (Flu). In vivo therapy of nude mouse xenografts tested Flu with gemcitabine (Gem) and/or bevacizumab (Bev).ResultsSeven of eight human PaCa cell lines expressed detectable AR protein. Median relative expression compared with the AR positive control LnCaP was 21% (range: 16 to 63). Growth stimulation by DHT or T was minor (<20%); inhibition by Flu varied greatly and did not correlate to AR levels. Even in the sensitive cell line Panc1, Flu failed to increase Gem toxicity in vitro. However, in vivo Flu therapy resulted in significant growth inhibition of Panc-1 tumors. Flu/Gem treatment did not enhance the effect; Bev/Flu/Gem triple therapy had the greatest effect (P = 0.06 compared to Flu/Gem). Flu alone did not affect apoptotic activity, but decreased the tumor cell proliferative index (P = 0.04); in combination with Gem, Flu reduced the tumor cell density (P = 0.02).ConclusionsThe majority of PaCa cell lines express AR at various levels, but most fail to show an in vitro antiproliferative response to AR inhibition. The strong antitumor effect of flutamide in vivo is not significantly enhanced in combination with gemcitabine or bevacizumab, suggesting primarily monotherapy benefit potential of AR blockade in susceptible PaCa.

This Beta program is not intended for use by Medical Professionals. To obtain this document through the Patient Research option you must have a medical need, only use the document for personal use, and agree to all the terms and conditions below. Also, these articles can be obtained for free at your local public or university hospital library. We encourage you to use this as a means of obtaining articles of interest to you.

Patient Research Terms and Conditions

The terms and conditions set out below govern your use of the content made available through this web-site (the "Site"), including the article or articles that you have selected in connection with your personal medical research (the "Content") for delivery to the e-mail address you will be asked to provide in connection with this service (collectively, the "Service"). In order to provide this Service you understand and agree to provide the personal information you will be asked to provide after you accept these terms and conditions, although our use of such information will be limited to this purpose and otherwise governed by our privacy policy (see Privacy Policy). The Content, the Site and the Service are provided by Elsevier Inc. and its affiliates and licensors (collectively "Elsevier"). For further information about Elsevier or to contact us, see Contact Us.

Permitted Uses

You may access in a given twenty-four hour period a reasonable number of Content items, and you may download and print such Content after it has been delivered to your e-mail address. Such access and use is for your own personal use, although you may also share and discuss such Content with family members and medical professionals involved in your medical care or the care of a family member. You can make further copies for such family members and medical professionals.

Prohibited Uses

Personal use does not include the use by researchers, instructors or students for research purposes or educational use.

You may not copy, display, distribute, modify, publish, reproduce, store, transmit, create derivative works from, or sell or license all or any part of the Content, or any other information obtained from or accessed through this Service in any medium to anyone. You may not modify in any way the text of the Content.

You may not use any robots, spiders, crawlers or other automated downloading programs or devices to: (i) continuously and automatically search or index the Site or the Content, unless authorized by us; (ii) harvest personal information from this web site for purposes of sending unsolicited or unauthorized material; or (iii) cause disruption to the working of the Service or this Site.

You may not use the Service or this Site to publish or distribute any advertising, promotional material, or solicitation to other users to use any goods or services.

Copyright Notice

All Content provided through this Service, and the Site layout, design, images, programs, text and other information displayed, are the property of Elsevier and is protected by copyright and other intellectual property laws.

Warranty

We will use reasonable efforts to respond to your requests for Content items and to maintain the indexes and other services involved in providing this Service and Site.

Disclaimer of Warranties and Liability

We make no other warranty whatsoever, including without limitation, that the operation of the Service or this Site will be uninterrupted or error-free; that defects will be corrected; that this Site, including the server that makes it available, is free of viruses or other harmful components; as to the results that may be obtained from use of the Content or other materials on the Site; or as to the accuracy, completeness, reliability, availability, suitability, quality, non-infringement or operation of any Content, product or service provided on or accessible from the Site.

THIS SERVICE, SITE AND ALL CONTENT, PRODUCTS AND SERVICES INCLUDED IN OR ACCESSIBLE FROM THIS SITE ARE PROVIDED "AS IS" AND WITHOUT WARRANTIES OR REPRESENTATIONS OF ANY KIND (EXPRESS, IMPLIED AND STATUTORY, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF TITLE AND NONINFRINGEMENT AND THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE), ALL OF WHICH NAME DISCLAIMS TO THE FULLEST EXTENT PERMITTED BY LAW. YOUR USE OF THE SITE IS AT YOUR SOLE RISK.

To the extent permissible under applicable laws, no responsibility is assumed for any injury and/or damage to persons, animals or property as a matter of products liability, negligence or otherwise, or from any use or operation of any ideas, instructions, methods, products or procedures contained in the Content or on this Site. If the Content items provided through the Service provide information about medical diagnoses and treatment, it is intended for professional use within the medical field. No suggested test or procedure should be carried out unless, in the judgment of a medical professional, its risk is justified. Because of rapid advances in the medical sciences, we recommend that the independent verification of diagnoses and drug dosages should be made. Discussions, views, and recommendations as to medical procedures, products, choice of drugs, and drug dosages are the responsibility of the authors.

WE SHALL NOT BE LIABLE TO YOU OR ANYONE ELSE FOR ANY LOSS OR INJURY, CAUSED IN WHOLE OR PART BY ITS NEGLIGENCE OR CONTINGENCIES BEYOND ITS CONTROL IN PROCURING, COMPILING, INTERPRETING, REPORTING OR DELIVERING INFORMATION THROUGH THE SITE. IN NO EVENT WILL WE BE LIABLE TO YOU OR ANYONE ELSE FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE ON SUCH INFORMATION. WE SHALL NOT BE LIABLE TO YOU OR ANYONE ELSE FOR ANY DAMAGES (INCLUDING, WITHOUT LIMITATION, CONSEQUENTIAL, SPECIAL, INCIDENTAL, INDIRECT, OR SIMILAR DAMAGES) EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

Governing Law and Venue

These terms and conditions shall be governed by and construed in accordance with the laws of the State of New York, without regard to its conflicts of law principles. You hereby submit to and agree that the sole jurisdiction and venue for any actions that may arise under or in relation to the subject matter hereof shall be the courts located in the State of New York.

Last revised: 10/2006

I have read and agree to the terms and conditions above

 

Copyright © 2007 Elsevier Inc.
All rights reserved.
Contact Us | Terms & Conditions | Privacy Policy | About